Lisa Niswander, MD, PhD

2023

Niswander LM*, Graff ZT*, Chien CD*, Chukinas JA, Meadows CA, Leach LC, Loftus JP, Kohler ME, Tasian SK#, Fry TJ#: Potent preclinical activity of FLT3-directed CAR T cell immunotherapy against FLT3-mutant AML and KMT2A-rearranged ALL. Hematologica 108(2): 457-471, February 2023.

Niswander LM, Chung P, Diorio C, and Tasian SK: Clinical responses in pediatric patients with relapsed/refractory leukemia treated with azacitidine and venetoclax. Haematologica Online ahead of print, April 2023.

2021

Niswander LM*, Loftus JP*, Lainey E, Caye-Eude A, Pondrom M, Hottman DA, Iacobucci I, Mullighan CG, Jain N, Konopleva M, Cave G, Baruchel A, Rohrlich PS, and Tasian SK: Therapeutic potential of ruxolitinib and ponatinib in patients with EPOR-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia. Haematologica 106(10): 2763-2767, 2021.

Qin H, Yang L, Chukinas JA, Shah NN, Tarun S, Pouzolles M, Chien CD, Niswander LM, Welch AR, Taylor NA, Tasian SK, Fry TJ: Systematic Preclinical Evaluation of CD33-Directed Chimeric Antigen Receptor T Cell Immunotherapy for Acute Myeloid Leukemia Defines Optimized Construct Design. Journal for ImmunoTherapy of Cancer 9: e003149, 2021.

Saunders J, Niswander LM, McGrath KM, Koniski A, Catherman SC, Ture SK, Medhora M, Kingsley PD, Calvi LM, Williams JP, Morrell CN, and Palis J:  Long-acting PGE2 and lisinopril mitigate H-ARS.  Radiation Research 196(3): 284-296, 2021.

2020

Loftus JP, Yahiaoui A, Brown PA, Niswander LM, Bagashev A, Wang M, Schauf A, Tannheimer, Tasian SK: Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia.  Haematologica 106(4): 1067 - 1078, 2020.

2014

Niswander LM, Cromwell P, Gupton A, Chirico J, Korones DN: End-of-life care for children enrolled in a community-based pediatric palliative care program. Journal of Palliative Medicine 17(5): 589-591, 2014.

Niswander LM, Fegan KH, Kingsley PD, McGrath KE and Palis J: SDF-1 mediates megakaryocyte niche occupancy and thrombopoiesis at steady-state and following radiation injury Blood 124: 277 - 286, 2014 Notes: Accompanying "Inside Blood" commentary:Thon, JN. SDF-1 directs megakaryocyte relocation. Blood, 124: 161-163, 2014.

Niswander LM, McGrath KE, Kennedy JC, Palis J: Improved quantitative analysis of primary bone marrow megakaryocytes utilizing imaging flow cytometry. Cytometry A 85(4): 302 - 312, 2014 Notes: Accompanying commentary:Filby, A. "Mega" Cytometry for a "mega" challenging cell type. Cytometry A, 85(4): 289-291, 2014.

2011

Carbajal L, Biswas A, Niswander LM, Prizant H, Hammes SR: GPCR/EGFR cross talk is conserved in gonadal and adrenal steroidogenesis but is uniquely regulated by matrix metalloproteinases 2 and 9 in the ovary. Molecular Endocrinology 25: 1055 - 1065  2011.

2007

Kim S, Namekawa SH, Niswander LM, Ward JO, Lee JT, Bardwell VJ, Zarkower D : A Mammal-Specific Doublesex Homolog Associates with Male Sex Chromatin and Is Required for Male Meiosis  PLoS Genetics 3(4): e62, 2007 Notes: DOI:10.1371/journal.pgen.0030062.

Ward JO, Reinholdt LG, Motley WW, Niswander LM, Deacon DC, Griffin, LB, Langlais KK, Backus VL, Schimenti KJ, O'Brien MJ, Eppig JJ, Schimenti, JC : Mutation in Mouse Hei10, an E3 Ubiquitin Ligase, Disrupts Meiotic Crossing Over. PLoS Genetics 3(8): e139, 2007 Notes: DOI: 10.1371/journal.pgen.0030139.

2022

Niswander LM, Chung P, Diorio C, Tasian SK: Single-Institution Clinical Experience with Azacitidine and Venetoclax +/- Gemtuzumab in Pediatric Patients with Relapsed or Refractory Acute Leukemias. Poster presentation at Children's Oncology Group Fall Meeting  Sept 2022.

Niswander LM, Chung P, Diorio C, Tasian SK: Clinical Experience with Azacitidine and Venetoclax +/- Gemtuzumab in Pediatric Patients with Relapsed or Refractory Acute Leukemias: A Report from the Children's Hospital of Philadelphia. Poster Presentation at the American Society of Hematology Annual Meeting Dec 2022.

2021

Niswander LM, Chukinas JA, Graff Z, Bagashev A, Leach L, Fry TJ, and Tasian SK: Targeting of FLT3 with Chimeric Antigen Receptor T Cell Immunotherapy and Tyrosine Kinase Inhibition in High-Risk Pediatric Leukemias. Abstract for oral presentation at the American Society of Hematology Annual Meeting December 2021.

2022

Niswander LM. "Combinatorial targeting of FLT3 in high risk pediatric leukemias," Child Health Research Centers Virtual Annual Meeting. Oct 2022.

Niswander LM. "Multimodal targeting of FLT3 in high risk pediatric leukemias", University of Minnesota Combined Adult/Pediatric Bone Marrow Transplant Virtual Subspecialty Grand Rounds. May 2022.

2021

Niswander LM. "Combination immunotherapeutic and molecular targeting of FLT3 in pediatric leukemias." Pediatric Immunotherapy Discovery and Development Network (PI-DDN), Virtual Annual Meeting. Nov 2021.

Niswander LM. "Multimodal targeting of FLT3 in high risk pediatric leukemias." Acute Lymphoblastic Leukemia Research and Care Network (ALL RCaN) Virtual Meeting. Sept 2021.

Niswander LM. "Multimodal targeting of FLT3 signaling with chimeric antigen receptor T cell immunotherapy and tyrosine kinase inhibition in high-risk pediatric leukemias." Hematologic Malignancies Section, Pediatric Oncology Branch, National Cancer Institute Virtual Meeting. Feb 2021.

Niswander LM. "Multimodal targeting of FLT3 signaling with chimeric antigen receptor T cell immunotherapy and tyrosine kinase inhibition in high-risk pediatric leukemias." Pediatric Immunotherapy Discovery and Development Network (PI-DDN), Steering Committee Virtual Meeting. Jan 2021.

2014

Niswander LM, Palis J, McGrath KE : Imaging flow cytometric analysis of primary bone marrow megakaryocytes. Imaging Flow Cytometry - Methods and Protocols, Methods in Molecular Biology. New York, NY (eds.). Springer, 1389: 265 - 277, 2014 Notes: Chapter 19; https://doi.org/10.1002/cyto.a.22438.